[1].Siegel, R.L., K.D. Miller and A. Jemal, Cancer Statistics, 2017. CA Cancer J Clin, 2017. 67(1): p. 7-30.
[2].Torre, L.A., et al., Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev, 2016. 25(1): p. 16-27.
[3].Ohashi, S., et al., Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma. Gastroenterology, 2015. 149(7): p. 1700-15.
[4].Pickens, A. and M.B. Orringer, Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg, 2003. 76(4): p. S1367-9.
[5].Vizcaino, A.P., et al., Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer, 2002. 99(6): p. 860-8.
[6].Lam, K.Y., L.T. Ma and J. Wong, Measurement of extent of spread of oesophageal squamous carcinoma by serial sectioning. J Clin Pathol, 1996. 49(2): p. 124-9.
[7].Rustgi, A.K. and H.B. El-Serag, Esophageal carcinoma. N Engl J Med, 2014. 371(26): p. 2499-509.
[8].Pennathur, A., et al., Oesophageal carcinoma. Lancet, 2013. 381(9864): p. 400-12.
[9].Mariette, C., et al., Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer, 2003. 97(7): p. 1616-23.
[10]. Javle, M., et al., Palliation of malignant dysphagia in esophageal cancer: a literature-based review. J Support Oncol, 2006. 4(8): p. 365-73, 379.
[11]. Gertler, F.B., et al., Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics. Cell, 1996. 87(2): p. 227-39.
[12]. Di Modugno, F., et al., The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors. Clin Cancer Res, 2006. 12(5): p. 1470-8.
[13]. Wang, W., et al., Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res, 2002. 62(21): p. 6278-88.
[14]. Bear, J.E., et al., Antagonism between Ena/VASP proteins and actin filament capping regulates fibroblast motility. Cell, 2002. 109(4): p. 509-21.
[15]. Krause, M., et al., Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol, 2003. 19: p. 541-64.
[16]. Barzik, M., et al., Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. J Biol Chem, 2005. 280(31): p. 28653-62.
[17]. Fan T, Chen J, Zhang L, et al. Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway[J]. Mol Cancer, 2016,15:23
[18]. Bong, A. and G.R. Monteith, Breast cancer cells: Focus on the consequences of epithelial-to-mesenchymal transition. Int J Biochem Cell Biol, 2017. 87: p. 23-26.
[19]. Thiery J P, Acloque H, Huang R Y, et al. Epithelial-mesenchymal transitions in development and disease[J]. Cell, 2009,139(5):871-890.
[20]. Batlle, E., et al., The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol, 2000. 2(2): p. 84-9.
[21]. Kessenbrock, K., V. Plaks and Z. Werb, Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 2010. 141(1): p. 52-67.
[22]. Verslegers, M., et al., Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system. Prog Neurobiol, 2013. 105: p. 60-78.
[23]. Hofmann, U.B., et al., Matrix metalloproteinases in human melanoma. J Invest Dermatol, 2000. 115(3): p. 337-44.
[24]. Hoxhaj, G. and B.D. Manning, The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer, 2019.
[25]. Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors[J]. Curr Opin Cell Biol, 2005,17(5):559-564.
[26]. Murphy, D.A. and S.A. Courtneidge, The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol, 2011. 12(7): p. 413-26.
[27] Philippar U, Roussos E T, Oser M, et al. A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis[J]. Dev Cell, 2008,15(6):813-828.
[28]. Karnoub, A.E., et al., Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 2007. 449(7162): p. 557-63.
[29]. Hay, E.D., The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn, 2005. 233(3): p. 706-20.
[30]. Shibue, T. and R.A. Weinberg, EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol, 2017. 14(10): p. 611-629.
[31]. Thiery, J.P., et al., Epithelial-mesenchymal transitions in development and disease. Cell, 2009. 139(5): p. 871-90.
[32]. Wang, L.T., et al., Transcription factor SPZ1 promotes TWIST-mediated epithelial-mesenchymal transition and oncogenesis in human liver cancer. Oncogene, 2017. 36(31): p. 4405-4414.
[33]. Arcaro A, Guerreiro A S. The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications[J]. Curr Genomics, 2007,8(5):271-306.
[34]. Brognard J, Hunter T. Protein kinase signaling networks in cancer[J]. Curr Opin Genet Dev, 2011,21(1):4-11.
[35]. Roussos, E.T., et al., Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci, 2011. 124(Pt 13): p. 2120-31.
[36]. Goswami, S., et al., Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis, 2009. 26(2): p. 153-9.
[37]. Oudin, M.J., et al., Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression. Cancer Discov, 2016. 6(5): p. 516-31.
[38]. Di Modugno, F., et al., hMENA isoforms impact NSCLC patient outcome through fibronectin/beta1 integrin axis. Oncogene, 2018. 37(42): p. 5605-5617.
[39]. Di Modugno, F., et al., Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. Cancer Res, 2007. 67(6): p. 2657-65.
[40]. Tanaka, N., et al., Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma. Int J Oncol, 2014. 45(5): p. 1921-8.